Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include NeurologyLive, Reuters, Bloomberg.com and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 25d ago.
Quick answers
Why is "Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in l" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Bristol reports patient death in early trial of CAR-T therapy for multiple sclerosis Seeking Alpha · 25d ago
- Patient Death Reported in Bristol Myers Squibb Autoimmune Study WSJ · 25d ago
- CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study NeurologyLive · 25d ago
- Bristol Myers discloses patient death in early-stage cell therapy study Reuters · 25d ago
- Bristol Myers Reports CAR-T Death as Safety Concerns Mount Bloomberg.com · 25d ago
- Patient dies in Bristol Myers Squibb autoimmune CAR-T trial STAT · 25d ago
- Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial Endpoints News · 25d ago
Topics
Related trends
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
How Maya Jama went from Bristol native to Celebrity Traitors star
Maya Jama garners widespread praise for a generous charity donation following a high-stakes betrayal in the finale of Celebrity Traitors.
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
Caribou Biosciences, a biotech firm co-founded by Nobel laureate Jennifer Doudna, is halting its pipeline and reducing staff amid potential closure.
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
Adicet Bio's experimental CAR-T therapy sparks early lupus remissions, drawing widespread industry attention.
Carson Hocevar, Ryan Blaney trade niceties a week after Bristol fight
Carson Hocevar and Ryan Blaney trade niceties following their widely covered Bristol Motor Speedway brawl.
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna advances its cell therapy toward an FDA submission as new one-year durability data emerges.